Member Info for LTbeliever

It's buy and hold for the rest of us Davey, AFS next month and AGM, more positive things to come; soon, sub-4p will be history IMO.

Final comment FFX; you may call me naive or overoptimistic, but, perhaps you also allow yourself to be too pessimistic by dwelling on the past failures too much? At the end of the day, NFX got EMA and FDA ODD in the past 12 months (and burned 600-700k in the process), managed to get 1mln of fresh funds, it's conducting new studies specifically requested by interested parties (potential, as yet, partners), so you have to admit there has been some progress and NFX is getting closer to the finish line. Have you considered the "cost" of you being wrong i.e. in 2-3 months 1-2 deals are announced?

If you are right, it means you are stuck in a stock going nowhere; if you are wrong?

FFX, TR1 is issued when you reach a threshold of o/ship, not how long you hold; it's not Dan's fault if CMC is flogging the new shares to the "wrong' type of investors; Dan is focused on the studies and the discussions with partners - NDAs are customary in industry as everyone completes against everyone, if the partners are demanding confidentiality, NFX has to adhere to the request.

500mln new shares (24% of pre-placing SCap) have been issued, I don't think that there have been 500mln shares sold this past week (since oDD was announced); but if the new investors sold out, somebody else bought those shares with a longer term view; either way, selling should soon subside IMO.

My thoughts exactly, Tdesk! Placees must have been given some assurances about near term progress; and as you rightly say, no warrants (=further dilution) have been given, which implies that the Placees were "satisfied" with what they received (promise of high returns, IMO).

FFX, I see why you have those views given the past "false dawns"; regarding p/ship deals, I disagree as the ODD was granted just 1 week ago so a deal can still be announced in 1-2 months (this is my strong view); even if it takes a bit longer (3-4 months) due to the fresh data requested, I see 2 positives:

a) some investors (unknown) have been convinced to fork out 1mln in - using your words - this "bottomless pit" - WHY? are they stupid/blind/naive? Don't they have better investing opportunities? IMO, they are aware of what's gonna happen and when (soon, IMO);

b) precious funds are earmarked for "additional studies"; again IMO, why throw money away unless the Co expects - with a high probability, not 100% certainty - that these requests will lead to a deal or deals?

Davey, I agree; with ships stranded in every ocean, crime/theft and fraud going up exponentially, demand for T42's services are bound to go on rising, IMO.

Hi Laura, he's a Director of many UK companies, as per CO House; maybe he knows G Watt well and he's "seen" something" in PIP?

FFX, despite all the past failures etc, have you ever considered averaging down? At this SP, do you still think it's not worth buying?

A couple of false dawns last July & August due to severe profit taking on good RNSs, IMO this is different as the SP rise is on no news so might be in "insider" job!

Steady buying, now 8% - does he know something we don't? May he continue buying.

Copying from 9 March:

I am looking at 10p by September interims, which should show a minimum of 4.5-5mln in Sales

3.10 - 2.80

Looks like a TR1 should be coming out soon.

Unless we get a "miracle" RNS on a p/ship sometime in April, next RNS should be the Interim report (to 30 March 2026) in May.

Well, if you and Spodulike are correct then tomorrow the SP should bottom out. Let's see what happens. GLA!

FFXS, you are assuming that the IIs were kept in the dark, like the rest of us; but think about it, you have Dan/CMC asking for a cool 1mln for NFX, don't u think the IIs were "given a positive story" about the near future?

Spod, yes selling at over 0.20 would make sense to fwd sell; if I am an IInv investing in a Placing at 0.20, I do it because I expect the SP to be higher (or much higher) in a few weeks/months hence; so why still sell at 0.20?

Tnx Spodulike, so it almost certain that on ODD's release, the insiders started selling given that they were due to get fresh stock at 0.20; the question now is, who is still selling at 0.20?? Is it speculators caught out by the ODD not shooting up, is it re war jitters etc?

This is also a good article (1 year old) on the IPF market's challenges and opportunities; IMO, it means that whoever "goes to bed" with NFX has a good chance of making a handsome return on its investment, by using NPX0002 as part of a combination therapy. Alternative views welcome!

https://www.bigpharmasharma.com/p/a-crucial-moment-in-ipf-what-boehringer

"With Roche stepping aside and Boehringer Ingelheim surging ahead, the IPF market has entered a new era. For years, IPF drug development was defined by high hopes followed by disappointment, but now, nerandomilast has broken the cycle. The next two years will determine whether this is the beginning of a new wave of innovation in IPF or if the field remains a high-risk, low-reward battleground. Boehringer Ingelheim now has the clear lead, but competition could emerge if companies begin exploring combination strategies or novel mechanisms beyond fibrosis and inflammation alone. For now, though, IPF belongs to Boehringer—and everyone else will have to play catch-up."

I only found one (2 links) from Jan. 2025, Eli Lilly paying $99mln upfront fee & 687mln further out, subject to milestones (note - this is for a Phase I drug i.e. some way ahead of where NFX is now). Question is, how much will NFX get, at the pre-clinical stage? Its 2022 presentation stated an average pmnt of $67mln (average of 2 deals).

"Mediar Therapeutics stands to gain an upfront payment and near-term milestones totaling $99 million. Additionally, the partnership could yield up to $687 million in further payments tied to commercialization achievements".

https://www.agentcapital.com/2025/01/lilly-ventures-into-pulmonary-fibrosis-with-startup-mediar/

https://synapse.patsnap.com/article/mediar-therapeutics-and-eli-lilly-ink-ipf-treatment-licensing-deal